- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SCIBASE Aktie jetzt für 0€ handeln | |||||
| 26.09. | SciBase: Nevisense Used in Fundamental Skin Barrier Research on Atopic Dermatitis | 229 | PR Newswire | STOCKHOLM, Sept. 26, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, announced today the publication... ► Artikel lesen | |
| 23.09. | SciBase receives initial order for clinical study from Castle Biosciences | 257 | PR Newswire | STOCKHOLM, Sept. 23, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has... ► Artikel lesen | |
| 10.09. | Main owners strengthen their position in SciBase | 242 | PR Newswire | STOCKHOLM, Sept. 10, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that Ribbskottet... ► Artikel lesen | |
| 28.08. | SciBase: New Clinical Publication in Karger Dermatology Confirms Reader Studies as Key to Validating Nevisense | 269 | PR Newswire | STOCKHOLM, Aug. 28, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces the recent publication... ► Artikel lesen | |
| 19.08. | SciBase: Interim report | 334 | PR Newswire | STOCKHOLM, Aug. 19, 2025 /PRNewswire/ --
January 1 - June 30, 2025
The second quarter in figures
Net sales were TSEK 8,791 (6,641), +32%, cleared for currency effects +40%.The... ► Artikel lesen | |
| 01.08. | SciBase announces outcome in directed share issue | 359 | PR Newswire | STOCKHOLM, Aug. 1, 2025 /PRNewswire/ -- On 16 June 2025, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's Board of Directors resolved, pursuant to the authorisation... ► Artikel lesen | |
| 09.07. | SciBase Launches Nevisense Pilot at Leading University in Southeast Florida | 242 | PR Newswire | STOCKHOLM, July 9, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that a... ► Artikel lesen | |
| 07.07. | SciBase: A new important customer in the US, Palm Beach Dermatology Group, has placed an initial order for 6 Nevisense. | 289 | PR Newswire | STOCKHOLM, July 7, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, is pleased to announce... ► Artikel lesen | |
| 30.06. | SciBase announces outcome in directed share issue | 194 | PR Newswire | STOCKHOLM, June 30, 2025 /PRNewswire/ -- On 23 June 2025, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's board of directors resolved, pursuant to the... ► Artikel lesen | |
| 23.06. | SciBase resolves on a directed share issue of approximately SEK 11 million | 325 | PR Newswire | STOCKHOLM, June 23, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, in accordance with the intention published by the Company... ► Artikel lesen | |
| 17.06. | Bulletin from the annual general meeting in SciBase Holding AB (publ) | 419 | PR Newswire | STOCKHOLM, June 17, 2025 /PRNewswire/ -- Today, the annual general meeting 2025 has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance... ► Artikel lesen | |
| 17.06. | SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30 | 382 | PR Newswire | STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed... ► Artikel lesen | |
| 16.06. | Castle Biosciences partners with SciBase for diagnostic tests | 1 | Seeking Alpha | ||
| 16.06. | SciBase resolves on a directed share issue of SEK 19 million and announces its intention to carry out an additional directed share issue of approximately SEK 11 million | 431 | PR Newswire | STOCKHOLM, June 16, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, pursuant to the authorisation granted by the annual general... ► Artikel lesen | |
| 16.06. | Castle Biosciences partners with SciBase to develop atopic dermatitis test | 1 | Investing.com | ||
| 16.06. | Castle Biosciences, Inc.: Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases | 187 | GlobeNewswire (Europe) | FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it... ► Artikel lesen | |
| 09.06. | SciBase Initiates Self-Pay Model in the US to Make Nevisense Test More Accessible to Patients | 330 | PR Newswire | STOCKHOLM, June 9, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced the launch... ► Artikel lesen | |
| 04.06. | SciBase Expands Further Through European Market with First Sales Order to customer in Italy | 252 | PR Newswire | STOCKHOLM, June 4, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced its first... ► Artikel lesen | |
| 27.05. | SciBase reaches milestone with over 300,000 patients tested with Nevisense | 258 | PR Newswire | STOCKHOLM, May 27, 2025 /PRNewswire/ -- SciBase Holding AB ('SciBase') (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced a major... ► Artikel lesen | |
| 23.05. | SciBase publishes the Annual report for 2024 | 307 | PR Newswire | STOCKHOLM, May 23, 2025 /PRNewswire/ -- SciBase hereby announces that the Annual report for 2024 is available at the Company's website www.scibase.com.
A pdf-version of the annual report... ► Artikel lesen |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ROKU | 81,76 | -3,41 % | Access Advance HEVC and Video Distribution Pool Patent Owners Bring Streaming and Device Patent Infringement Suit Against Roku in Brazil | BOSTON, MA / ACCESS Newswire / October 14, 2025 / Access Advance LLC today announced that certain patent owners in the HEVC Advance and Video Distribution Patent Pools have filed patent infringement... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,115 | +8,49 % | Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - October 1, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH0) ("Sernova") a leading regenerative medicine company focused... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 84,60 | +0,71 % | Boston Scientific stock rating reiterated at Buy by TD Cowen | ||
| PAUL HARTMANN | 226,00 | -0,88 % | Januar bis Juni 2025: PAUL HARTMANN behauptet sich in herausforderndem Marktumfeld | Heidenheim (ots) - - Umsatzerlöse steigen auf 1.214,0 Mio. EUR, organisches Umsatzwachstum von 1,6 % - Bereinigtes EBITDA liegt bei 125,8 Mio. EUR, bereinigte EBITDA-Rendite bei 10,4 % - Transformationsprogramm... ► Artikel lesen | |
| SYSMEX | 10,300 | -1,90 % | Goldman Sachs upgrades Sysmex stock to Buy on growth re-evaluation | ||
| ADDLIFE | 16,100 | -3,77 % | AddLife AB: Interim Report January 1 - June 30, 2025 | Continued improvement in margins and profit"The companies within AddLife continue to develop in line with our priorities. Margins are strengthening in both business areas thanks to continuous development... ► Artikel lesen | |
| EMBECTA | 11,900 | -0,83 % | Dividendenbekanntmachungen (29.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACNB CORPORATION US0008681092 0,34 USD 0,2911 EUR ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,18 USD 0,1541 EUR AEBI SCHMIDT HOLDING... ► Artikel lesen | |
| ENOVIS | 26,800 | 0,00 % | Enovis Corporation: Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million | Wilmington, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Enovis Corporation ("Enovis" or "the Company") (NYSE: ENOV), an innovation-driven medical technology growth company, today announced the sale of its... ► Artikel lesen | |
| KANGJI MEDICAL | 0,965 | 0,00 % | Kangji Medical Holdings Limited: Kangji Medical and Knight Bidco Jointly Dispatch Scheme Document for Privatisation Proposal | HONG KONG, Oct 13, 2025 - (ACN Newswire) - Kangji Medical Holdings Limited ('Kangji Medical' or the 'Company', Stock Code: 9997.HK) and Knight Bidco Limited (the 'Offeror') today announced that a circular... ► Artikel lesen | |
| PULMONX | 1,350 | 0,00 % | Pulmonx Corporation: Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025 | ||
| KOOTH | 1,600 | +1,27 % | Kooth inks contract with New Jersey for further year under same terms | ||
| PEIJIA MEDICAL | 0,705 | 0,00 % | PEIJIA-B (09996): VOLUNTARY ANNOUNCEMENT - REGISTRATION APPLICATION FOR GEMINIONE TRANSCATHETER EDGE-TO-EDGE REPAIR SYSTEM ACCEPTED BY THE NMPA | ||
| SI-BONE | 12,700 | -1,55 % | SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance | Second Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.6 million, representing growth of 21.7%U.S. revenue of $46.4 million, representing... ► Artikel lesen | |
| LIFECARE ASA | 0,646 | +7,31 % | Lifecare ASA: Mandatory notification of trade | ||
| BACTIGUARD | 1,515 | 0,00 % | BACTIGUARD HOLDING AB: Invitation to presentation of Bactiguard's interim report for the third quarter 2025 |
Das Unternehmen SCIBASE HOLDING AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,006 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCIBASE HOLDING AB finden Sie auf Wallstreet Online.